COEP

Coeptis Therapeutics Holdings Inc

Add to Watchlist

Advanced Chart

11.130

-0.05(-0.447%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.238

Open

11.200

VWAP

11.16

Vol

30.83K

Mkt Cap

39.28M

Low

11.040

Amount

343.95K

EV/EBITDA(TTM)

Total Shares

37.12M

37.99M

EV/OCF(TTM)

P/S(TTM)

399.83

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q4

FY2024Q3

FY2024Q2

-0.800

-39.7%

-1.000

-78.26%

-1.800

+1416.43%

Estimates Revision

The market is revising No Change the revenue expectations for Coeptis Therapeutics Holdings, Inc. (COEP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 12.99%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+12.99%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Coeptis Therapeutics Holdings Inc (COEP.O) is -3.25, compared to its 5-year average forward P/E of -17.76. For a more detailed relative valuation and DCF analysis to assess Coeptis Therapeutics Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.76

Current PE

-3.25

Overvalued PE

22.35

Undervalued PE

-57.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.14

Current EV/EBITDA

-2.69

Overvalued EV/EBITDA

0.48

Undervalued EV/EBITDA

-4.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.76

Current PS

0.00

Overvalued PS

15.60

Undervalued PS

-6.09

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Financials

Annual

Quarterly

FY2025Q1

62.87K

Total Revenue

FY2025Q1

YoY :

+38.82%

-4.06M

Operating Profit

FY2025Q1

YoY :

+13.98%

-3.42M

Net Income after Tax

FY2025Q1

YoY :

-40.83%

-1.00

EPS - Diluted

FY2025Q1

YoY :

+24.38%

-2.37M

Free Cash Flow

FY2025Q1

-369.44

Gross Profit Margin - %

FY2025Q1

-5.44K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

COEP News & Events

Events Timeline

2025-07-22 (ET)

2025-07-22

08:38:38

Coeptis Therapeutics extinguishes convertible note

2025-06-26 (ET)

2025-06-26

08:37:23

Coeptis files registration statement for proposed Z Squared transaction

2025-05-28 (ET)

2025-05-28

08:29:40

Monarch Therapeutics, SNAP Biosciences enter licensing agreement

News

7.0

07-05Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders

8.5

06-26Newsfilter

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

8.5

05-12Newsfilter

NUBURU Files $100M SEC Registration Statement to Enhance Capital Flexibility for Completion of Defense Acquisition and Blue Laser Technology Revitalization Targeting a $500B Defense Market